Neovacs: Investor Presentation (Neovacs) - Jul 3, 2015 - “Good safety profile of IFNα-Kinoid at each dose level (few local or systemic reactions, only one flare reported as SAE)”; “All patients developed binding anti-IFNα antibodies. Higher production of binding and neutralizing antibodies in patients with more severe lupus”; “Those antibodies neutralize all 13 subtypes of IFNα, in contrast with monoclonal anti-IFNα antibodies (2 subtypes only are completely neutralized)”; “Improvement of disease biomarkers (IFN signature & C3) is correlated with the intensity and duration of the neutralizing response”; “Follow up until decline of anti-IFNα antibodies of 5 patients with a tapering in CS and no flare 3 years after dosing”
P1/2 data • Immunology • Lupus
|